SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-18-002091
Filing Date
2018-02-14
Accepted
2018-02-14 12:11:55
Documents
35
Period of Report
2017-12-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 184564
2 ex31-1.htm EX-31.1 18007
3 ex31-2.htm EX-31.2 17998
4 ex32-1.htm EX-32.1 6564
5 ex32-2.htm EX-32.2 6493
  Complete submission text file 0001493152-18-002091.txt   1147770

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE ntva-20171231.xml EX-101.INS 118639
7 XBRL SCHEMA FILE ntva-20171231.xsd EX-101.SCH 16527
8 XBRL CALCULATION FILE ntva-20171231_cal.xml EX-101.CAL 22524
9 XBRL DEFINITION FILE ntva-20171231_def.xml EX-101.DEF 62863
10 XBRL LABEL FILE ntva-20171231_lab.xml EX-101.LAB 112712
11 XBRL PRESENTATION FILE ntva-20171231_pre.xml EX-101.PRE 94858
Mailing Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246
Business Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246 3034957583
Intiva BioPharma Inc. (Filer) CIK: 0001625288 (see all company filings)

IRS No.: 262049376 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-55320 | Film No.: 18609621
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1